ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1928

A Multicenter, Prospective Cohort Study Using Nailfold Videocapillaroscopy and Other Clinical Characteristics to Determine the Risk of Developing New Digital Ulcers in Patients with Systemic Sclerosis

Vanessa Smith1, Maurizio Cutolo2, Ariane Herrick3, Oliver Distler4, Mike Becker5, Emma Beltran6, Patrick Carpentier7, Clodoveo Ferri8, Murat Inanc9, Panayiotis Vlachoyiannopoulos10, Harbajan Chadha-Boreham11, Emmanuelle Cottreel11, Thomas Pfister11, Daniel Rosenberg11 and Juan Torres, on behalf of the CAP study investigators12, 1Ghent University Hospital, Ghent, Belgium, 2Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, 3Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, 5Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, 6Hospital La Fe, Valencia, Spain, 7Vascular Medicine, La Tronche Hospital, Grenoble, France, 8Rheumatology, University of Modena & Reggio E, Moderna, Italy, 9Rheumatology, Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, 10Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, 11Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 12Syntax for Science SL, Basel, Switzerland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: nailfold capillaroscopy, systemic sclerosis and ulcers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics II: Approaches to Cardiac and Vascular Manifestations in Systemic Sclerosis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Digital ulcers (DU) are painful and disabling and affect almost 50% of systemic sclerosis (SSc) patients. Nailfold videocapillaroscopy (NVC) non-invasively assesses SSc-related micro-angiopathy and may be useful in predicting clinical progression of digital vasculopathy, especially DU.1-4The objective of this study was to identify NVC variables and clinical characteristics which predict the occurrence of new DU in SSc patients.

Methods

International, prospective, multicenter cohort study in SSc. Eligibility was not restricted by medication use. SSc patients (American College of Rheumatology/LeRoy and Medsger) were enrolled in two strata: ‘DU History’ and ‘No DU History’. The No DU History patients had early disease (≤2 years).

Variables were classified into bundles for statistical analysis: demographics, SSc clinical characteristics, DU characteristics, NVC characteristics and other clinical characteristics. NVC variables for fingers II–V were evaluated locally in a standardized way. Patients were followed up to 6 months for new DUs (confirmed by the investigator).  Univariable Logistic Regression (ULR) was performed on all variables and Multivariable Logistic Regression (MLR) was performed within and across bundles to assess statistical significance (Wald chi-square p<0.15 for linear and p<0.05 for quadratic) and discriminatory ability (receiver operation characteristic area under the curve [ROC AUC]). Clinical relevance to predict new DU in 6 months was portrayed by model performance characteristics in a binary risk chart and two-by-two tables at different risk probability thresholds.

Results

Of the 623 patients enrolled in 59 centers, 591 had data on DU outcome (new DU or no new DU) during the study. 468 (79%) patients had a DU history, of whom 103 (22%) developed new DU. 123 (21%) patients had no DU history, of whom 5 (4%) developed new DU. Due to low event numbers in the no DU history group, the present analysis focuses on the DU history stratum. The mean age was 54.0 years, 79.5% were females, and 59.8% patients had limited cutaneous SSc. The final model consisted of the following 3 co-variables to predict the occurrence of DU within 6 months: number of DU at baseline visit categorized into 0, 1, 2 and ≥ 3, mean number of capillaries in the middle finger of the dominant hand (evaluated on two adjacent fields in the middle of the nailfold) and presence/absence of critical digital ischemia at enrolment. AUC of this model was 0.738 (C.I. 0.681-0.795). Internal validation through bootstrap generated AUC 0.633 [C.I. 0.510-0.756]). At a probability threshold of 37.3%, the binary risk table shows a specificity of 90.6%, a sensitivity of 39.4%, a negative predictive value (NPV) of 83.8% and a positive predictive value (PPV) of 54.9%.

Conclusion

The CAP study is the first and largest prospective study producing a simple prognostic model with acceptable performance which can be useful in the management of patients with presence or history of DU.

References

1. Cutolo M et al. Nature Rev Rheumatol 2010;6:578–87; 2. Smith V et al. Ann Rheum Dis 2011;70:180–3; 3. Sebastiani M et al. Ann Rheum Dis 2012;71:67–70; 4. Smith V et al. Ann Rheum Dis 2012;71:1636-9


Disclosure:

V. Smith,

Actelion Pharmaceuticals Ltd,

2;

M. Cutolo,

Actelion Pharmaceuticals Ltd,

2;

A. Herrick,

Actelion Pharmaceuticals US,

5,

Pfizer Inc,

5;

O. Distler,

Actelion Pharmaceuticals US,

5,

Pfizer Inc,

5,

Ergonex,

5,

Bristol-Myers Squibb,

5,

Bayer,

5,

United BioSource Corporation,

5,

Roche/Genentech,

5,

Medac,

5,

Biovitrium,

5,

Boehringer Ingelheim Pharma,

5,

Novartis Pharmaceutical Corporation,

5,

4D Science,

5,

Active Biotec,

5,

Sinoxa,

5,

Sanofi-Aventis Pharmaceutical,

5,

Serodapharma,

5,

GSK,

5,

Epipharm,

5;

M. Becker,
None;

E. Beltran,
None;

P. Carpentier,
None;

C. Ferri,
None;

M. Inanc,

Actelion Pharmaceuticals US,

5;

P. Vlachoyiannopoulos,
None;

H. Chadha-Boreham,

Actelion Pharmaceuticals US,

3;

E. Cottreel,

Actelion Pharmaceuticals US,

3;

T. Pfister,

Actelion Pharmaceuticals US,

3;

D. Rosenberg,

Actelion Pharmaceuticals US,

3;

J. Torres, on behalf of the CAP study investigators,

Actelion Pharmaceuticals US,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-multicenter-prospective-cohort-study-using-nailfold-videocapillaroscopy-and-other-clinical-characteristics-to-determine-the-risk-of-developing-new-digital-ulcers-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology